AccuImage qualifies for Over-the-Counter trading

Article

AccuImage qualifies for Over-the-Counter tradingThe OTC Bulletin Board has authorized AccuImage Diagnostics to begin trading its stock on the OTCBB under "AIDP" as of Oct. 23. The San Francisco-based imaging company counts year-to-date income

AccuImage qualifies for Over-the-Counter trading

The OTC Bulletin Board has authorized AccuImage Diagnostics to begin trading its stock on the OTCBB under "AIDP" as of Oct. 23. The San Francisco-based imaging company counts year-to-date income of $252,096 and revenue of $2.3 million and claims that its revenue has more than doubled over the same period in 1999. AccuImage develops three-dimensional visualization software, including products that enable 3-D Web-based PACS review, and digital image distribution and archiving technologies. The company is actively pursuing strategic alliances with equipment vendors and broadband providers.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.